ClinicalTrials.gg
Sign In
Status unknownNCT05631002Updated Nov 30, 2022

Chemical Shift Encoding-based Water-fat Magnetic Resonance Imaging in Spinal Tumors

An observational study in Spinal Tumor and Bone Tumor, sponsored by Peking University Third Hospital. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Peking University Third Hospital · Observational

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Sex
All
01

Study summary

Fat composition of the spinal tumors is positively correlated with classification and differential diagnosis of benign and malignant tumors.

Read the detailed description

Chemical shift encoding-based water-fat magnetic resonance imaging (MRI) is a non-invasive method that provides quantitative information about the biochemical water-fat composition of bone marrow and skeletal muscle in vivo.

02

Conditions studied

  • Spinal Tumor
  • Bone Tumor
03

In context

Spinal Cord Neoplasms

89 studies on the registry are indexed under Spinal Cord Neoplasms; 26 are open to participants now.

This study's planned enrollment of 150 is close to the median of 150 across 32 observational studies indexed under Spinal Cord Neoplasms.

Browse Spinal Cord Neoplasms studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 745 studies on the registry; 267 are open to participants now.

Browse Peking University Third Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with spinal tumors

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathological biopsy of a patient with diagnosed spinal tumor lesion, and preoperative examination Chemical shift encoding-based water-fat MRI was performed.

Exclusion criteria

Exclusion Criteria:

  • Recurrent neoplasms; Lesion diameter \< 1 cm; Poor image quality.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with benign spinal tumor

    Diagnostic Test: Chemical shift encoding-based water-fat MRI

  • Patients with intermediate spinal tumor

    Diagnostic Test: Chemical shift encoding-based water-fat MRI

  • Patients with malignant spinal tumor

    Diagnostic Test: Chemical shift encoding-based water-fat MRI

Interventions

  • Diagnostic testChemical shift encoding-based water-fat MRI

    Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method

06

What researchers measure

Primary outcomes

  1. Type of tumor

    Pathological diagnosis

    Time frame: One month before treatment

07

Study locations

1 of 1 sites recruiting
  • Peking University third hospital
    Beijing, Beijing Municipality 100089, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05631002
Lead sponsor
Peking University Third Hospital
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Aug 1, 2022
Primary completion
Dec 1, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Nov 30, 2022

Study contacts

Qizheng Wang
Contact
wangqizheng96@163.com
13161593501
Ning Lang
study chair · Peking University Third Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Spinal Cord Neoplasms →

Other studies from this sponsor

Peking University Third Hospital →

Start the discussion